American Lung Association (ALA) Lung Health Cohort
Study Details
Study Description
Brief Summary
The ALA-LHC is a longitudinal, multi-center cohort study that will enroll approximately 4,000 young adults between the ages of 25-35 who do not have severe lung disease. The overarching objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
The scientific goal of the study is to establish the relationship between a variety of factors (lifetime environmental exposures, fitness and physical activity, biomarkers, nasal respiratory epithelial transcriptome) and ideal versus impaired peak lung health (reserve and markers of susceptibility in investigators' model) in young adulthood. In addition to the initial baseline assessment, remote contacts (e.g., via text message, email, mail, or phone) at regular intervals will allow for both the retention of the participants as well as the collection of additional short-term follow-up information, i.e., within 4.5 years of enrollment. If additional funding becomes available, investigators will extend the study for an additional period of time to study factors related to long-term changes in lung health over time, i.e., at 5 years and beyond. Recruitment of participants will be conducted by the participating study sites along with national and regional efforts from the American Lung Association. Recruitment efforts will be supported by the study web site www.lung.org/lung-study
Study Design
Outcome Measures
Primary Outcome Measures
- Pre-bronchodilator measurement of Forced Expiratory Volume in one second (FEV1) [Baseline]
Pre-bronchodilator measurements of FEV1 to determine bronchoconstriction. FEV1 is measured in liters of air. Severity of bronchoconstriction is based on predicted values published by National Health and Nutrition Examination Survey (NHANES III hankinson) for height, weight and age. Predicted values are reported as percent predicted with a result of 80% or greater considered normal
- Pre-bronchodilator measurements of Forced Vital Capacity (FVC) [Baseline]
Pre-bronchodilator measurements FVC to determine lung volume. FVC is measured in liters of air. Participants predicted vital lung capacity is based on values published by National Health and Nutrition Examination Survey (NHANES III hankinson) for height, weight and age. Predicted values are reported as percent predicted with a result of 80% or greater considered normal
Eligibility Criteria
Criteria
Inclusion Criteria:
1- Age 25-35 years at the time of the baseline examination 2- Able to read and understand English or Spanish 3 -Has a social security number 4- Resident (citizen or non-citizen) of the United States (US) for at least 12 months prior to examination. Note: Individuals who are residents of the US who have temporarily spent time living outside of the US during the last 12 months (e.g., student exchange program, military posting) are eligible for participation.
5- Willing to provide contact information for at least 2 proxies who are likely to know the whereabouts and vital status of the participant
Exclusion Criteria:
-
Severe asthma, which is defined as any of the following:
-
Current (i.e. at the time of the visit) GINA Step 4 or higher therapy (medium dose ICS/LABA or high dose ICS or add-on LAMA; Medium dose = >250 fluticasone, propionate =100 fluticasone furoate, >200 beclomethasone, >400 budesonide, >220 mometasone). We will accept low-dose ICS/LABA or medium dose ICS.
OR
-
3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months OR
-
One asthma hospitalization in the past 12 months
-
History of any chronic lung disease other than asthma including but not limited to COPD, cystic fibrosis, pulmonary fibrosis, pulmonary hypertension
-
Current pregnancy
-
History of cancer other than non-melanoma skin cancer
-
Diagnosed cardiovascular diseases (i.e., congenital heart disease, coronary heart disease)
-
Inability to comply with study procedures, including
-
Inability or unwillingness to provide informed consent
-
Inability to perform study measurements
-
Inability to be contacted by phone (via calls and/or text messaging) or email
-
Any condition in the opinion of the physician that puts the participant at risk by participating in the study (e.g., serious respiratory illness requiring antibiotics or steroids or severe fever at the time of the study visit).
-
Institutionalization
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University Of Alabama | Birmingham | Alabama | United States | 35294 |
2 | University of Arizona-Tuscon | Tucson | Arizona | United States | 85724 |
3 | University of California, Los Angeles | Los Angeles | California | United States | 90095 |
4 | University of California, San Francisco | San Francisco | California | United States | 94143 |
5 | University of Colorado | Aurora | Colorado | United States | 80045 |
6 | National Jewish Health | Denver | Colorado | United States | 80206 |
7 | Nemours Children's Jacksonville | Jacksonville | Florida | United States | 32207 |
8 | University of Florida, Jacksonville | Jacksonville | Florida | United States | 32209 |
9 | University of Illinois at Chicago | Chicago | Illinois | United States | 60608 |
10 | Northwestern University | Chicago | Illinois | United States | 60611 |
11 | Rush Universtiy | Chicago | Illinois | United States | 60612 |
12 | University of Chicago | Chicago | Illinois | United States | 60637 |
13 | St. Vincent's Health System | Indianapolis | Indiana | United States | 46260 |
14 | University of Iowa | Iowa City | Iowa | United States | 52242 |
15 | University of Kansas | Kansas City | Kansas | United States | 66103 |
16 | Johns Hopkins University | Baltimore | Maryland | United States | 21218 |
17 | Brigham and Women's | Boston | Massachusetts | United States | 02115 |
18 | University of Michigan | Ann Arbor | Michigan | United States | 48109 |
19 | Presbyterian Brooklyn Methodist Hospital | Brooklyn | New York | United States | 11215 |
20 | New York Medical College | Hawthorne | New York | United States | 10532 |
21 | New York University | New York | New York | United States | 10016 |
22 | Mt. Sinai, NYC | New York | New York | United States | 10029 |
23 | Columbia University | New York | New York | United States | 10032 |
24 | Cornell University | New York | New York | United States | 10032 |
25 | University of Rochester | Rochester | New York | United States | 14642 |
26 | University of North Carolina Hospital | Chapel Hill | North Carolina | United States | 27517 |
27 | Duke University | Durham | North Carolina | United States | 27710 |
28 | Wake Forest School of Medicine | Winston-Salem | North Carolina | United States | 27104 |
29 | Ohio State University | Columbus | Ohio | United States | 43210 |
30 | Temple University | Philadelphia | Pennsylvania | United States | 19140 |
31 | University of Pittsburg-Emphysema/COPD Research Center | Pittsburgh | Pennsylvania | United States | 15213 |
32 | Medical University of South Carolina | Charleston | South Carolina | United States | 29425 |
33 | Vanderbilt University Medical Center | Nashville | Tennessee | United States | 37235 |
34 | Baylor College of Medicine | Houston | Texas | United States | 77030 |
35 | University of Vermont | Colchester | Vermont | United States | 05446 |
36 | University of Washington | Seattle | Washington | United States | 98108 |
37 | University of Wisconsin Madison | Madison | Wisconsin | United States | 53792 |
Sponsors and Collaborators
- Johns Hopkins University
- National Heart, Lung, and Blood Institute (NHLBI)
- American Lung Association
- Stanford University
Investigators
- Principal Investigator: Ravi Kalhan, MD, Northwestern University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRB00236497
- U01HL146408